15 LANDSCAPE OF SOMATIC MUTATION IN HEPATOCELLULAR CARCINOMA

viral breakthrough, 1 before week 12; HCV variants associated with asunaprevir and daclatasvir resistance were identified. Serious adverse events included 1 patient with hyperbilirubinemia and gastroenteritis, 3 with pyrexia and 1 hypochondriasis. Conclusions: The dual oral DAA combination of daclatasvir and asunaprevir, without peg-alfa/RBV, may offer a needed therapeutic alternative to peg-alfa/RBV-containing regimens for many patients, including some difficult-to-treat groups.